Search
Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. … [L939] It is the first treatment made available in the United States for Chagas disease.
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects … [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Categories: CD22 (Clusters of Differentiation 22) inhibitorsOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Synonyms: o-methyldiphenhydramine, o-monomethyldiphenhydramineMixtures: MYOGESIC-O, MYOGESIC-ORSutilain
go.drugbank.com/drugs/DB09379ApprovedWithdrawnOne gram of sutilain powder contains 250,000 casein units of proteolytic activity.[T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation.
Arbutamine
go.drugbank.com/drugs/DB01102Approveddiagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately . … Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in
Categories: Compounds used in a research, industrial, or household settingInosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice.
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. … Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand.
Synonyms: (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenineUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalL52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU. … [A187349] It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.
Products: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGE